IL286635A - tyk2 pseudokinase ligands - Google Patents
tyk2 pseudokinase ligandsInfo
- Publication number
- IL286635A IL286635A IL286635A IL28663521A IL286635A IL 286635 A IL286635 A IL 286635A IL 286635 A IL286635 A IL 286635A IL 28663521 A IL28663521 A IL 28663521A IL 286635 A IL286635 A IL 286635A
- Authority
- IL
- Israel
- Prior art keywords
- ligands
- tyk2 pseudokinase
- tyk2
- pseudokinase ligands
- pseudokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824144P | 2019-03-26 | 2019-03-26 | |
| PCT/US2020/024746 WO2020198379A1 (en) | 2019-03-26 | 2020-03-25 | Tyk2 pseudokinase ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286635A true IL286635A (en) | 2021-10-31 |
Family
ID=72612101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286635A IL286635A (en) | 2019-03-26 | 2021-09-23 | tyk2 pseudokinase ligands |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11780842B2 (enExample) |
| EP (1) | EP3946350A4 (enExample) |
| JP (1) | JP7595582B2 (enExample) |
| KR (1) | KR20220004641A (enExample) |
| CN (1) | CN113874021B (enExample) |
| AU (1) | AU2020247990A1 (enExample) |
| BR (1) | BR112021019070A2 (enExample) |
| CA (1) | CA3134814A1 (enExample) |
| EA (1) | EA202192625A1 (enExample) |
| IL (1) | IL286635A (enExample) |
| MX (1) | MX2021011723A (enExample) |
| SG (1) | SG11202110523XA (enExample) |
| WO (1) | WO2020198379A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| US20220177486A1 (en) * | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| SG11202110523XA (en) | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) * | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
| IL301385A (en) * | 2020-09-16 | 2023-05-01 | Alumis Inc | TYK2 inhibitors and their use |
| WO2022117090A1 (zh) * | 2020-12-03 | 2022-06-09 | 成都科岭源医药技术有限公司 | 一种多环化合物及其制备方法和用途 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| CN118084923A (zh) * | 2022-11-17 | 2024-05-28 | 中国科学院上海有机化学研究所 | 作为lrrk2激酶抑制剂的环状化合物及其制备方法 |
| EP4692096A4 (en) * | 2023-03-31 | 2026-07-22 | Prime Gene Therapeutics Co Ltd | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| JP4564485B2 (ja) | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US20070082900A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| US7517882B2 (en) | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| AU2017302019A1 (en) | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| KR102477063B1 (ko) * | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| AU2018230737B2 (en) | 2017-03-08 | 2022-09-22 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| IL317854A (en) * | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| EP3849981B1 (en) | 2018-09-10 | 2023-02-01 | Eli Lilly and Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| SG11202108619SA (en) | 2019-02-07 | 2021-09-29 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| US20220177486A1 (en) | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| SG11202110523XA (en) | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
-
2020
- 2020-03-25 SG SG11202110523XA patent/SG11202110523XA/en unknown
- 2020-03-25 EA EA202192625A patent/EA202192625A1/ru unknown
- 2020-03-25 CA CA3134814A patent/CA3134814A1/en active Pending
- 2020-03-25 JP JP2021556882A patent/JP7595582B2/ja active Active
- 2020-03-25 AU AU2020247990A patent/AU2020247990A1/en not_active Abandoned
- 2020-03-25 MX MX2021011723A patent/MX2021011723A/es unknown
- 2020-03-25 EP EP20777561.0A patent/EP3946350A4/en active Pending
- 2020-03-25 CN CN202080038590.0A patent/CN113874021B/zh active Active
- 2020-03-25 KR KR1020217034394A patent/KR20220004641A/ko not_active Ceased
- 2020-03-25 BR BR112021019070A patent/BR112021019070A2/pt not_active Application Discontinuation
- 2020-03-25 WO PCT/US2020/024746 patent/WO2020198379A1/en not_active Ceased
- 2020-03-25 US US17/441,788 patent/US11780842B2/en active Active
-
2021
- 2021-09-23 IL IL286635A patent/IL286635A/en unknown
-
2023
- 2023-08-28 US US18/457,070 patent/US20230406858A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020198379A1 (en) | 2020-10-01 |
| MX2021011723A (es) | 2021-10-22 |
| CA3134814A1 (en) | 2020-10-01 |
| EP3946350A1 (en) | 2022-02-09 |
| EA202192625A1 (ru) | 2022-03-21 |
| SG11202110523XA (en) | 2021-10-28 |
| EP3946350A4 (en) | 2022-09-07 |
| CN113874021A (zh) | 2021-12-31 |
| JP7595582B2 (ja) | 2024-12-06 |
| US20230406858A1 (en) | 2023-12-21 |
| JP2022529311A (ja) | 2022-06-21 |
| US11780842B2 (en) | 2023-10-10 |
| KR20220004641A (ko) | 2022-01-11 |
| CN113874021B (zh) | 2024-07-09 |
| US20220169651A1 (en) | 2022-06-02 |
| AU2020247990A1 (en) | 2021-11-11 |
| BR112021019070A2 (pt) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285429A (en) | tyk2 pseudokinase ligands | |
| SG11202110523XA (en) | Tyk2 pseudokinase ligands | |
| EP4054581A4 (en) | PSEUDOKINASE TYK2 LIGANDS | |
| ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB202018087D0 (en) | No details | |
| GB202013426D0 (en) | No Details | |
| GB202009212D0 (en) | No details | |
| GB201917229D0 (en) | No details | |
| GB202006205D0 (en) | No details | |
| GB201906221D0 (en) | No details | |
| GB202103639D0 (en) | No details | |
| IL315629A (en) | Biomolecules are radioactively labeled with 18F | |
| GB202008967D0 (en) | No details | |
| PL3845343T3 (pl) | Podstawa magnetyczna | |
| GB201900566D0 (en) | Carrier | |
| IL288304A (en) | Disc pump | |
| GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| HK40078169A (en) | Tyk2 pseudokinase ligands | |
| GB201903058D0 (en) | Adsorption | |
| GB201913937D0 (en) | Ligand Design | |
| GB2587869B (en) | Carrier | |
| GB201918871D0 (en) | Complexes | |
| GB201904518D0 (en) | Uvvyowgbrir circular | |
| GB202010443D0 (en) | No details | |
| GB201911303D0 (en) | Moleculaer complexes |